Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhance immune res ...

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology compan ...

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in "cold" tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38624 Vaccinex, Inc. (Exact name of Registrant as specified in its charter) Delaware 16-1603202 (State or other jurisdiction of incor ...

ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasdaq. Trading ...

ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that on December 16, 2024, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Pan ...

Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer’s disease. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 16-1603202 (State or other jurisdiction of incorp ...

Core Insights - Vaccinex, Inc. has signed multiple proprietary project agreements with major pharmaceutical companies, leveraging its ActivMAb® technology for antibody discovery [1][2] - The ActivMAb® platform is designed to express complex proteins, enabling the development of various antibody-based therapies targeting difficult membrane proteins [2][4] - The company is actively presenting its research at the Society for Immunotherapy of Cancer's 29th Annual Meeting, showcasing successful antibody discovery campaigns [2][3] Company Overview - Vaccinex is focused on treating neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D), with its lead drug candidate, pepinemab, currently in clinical trials [5][6] - Pepinemab is being evaluated in combination with KEYTRUDA® and BAVENCIO® for various cancer indications, including recurrent head and neck cancer and metastatic pancreatic adenocarcinoma [5][6] - The company holds global commercial and development rights to pepinemab and collaborates with Merck Sharp & Dohme Corp. for the KEYNOTE-B84 study [6] Technology and Innovation - The ActivMAb® technology allows for the discovery of antibodies specific to complex membrane antigens, which are often challenging for traditional drug development [2][4] - The platform has already led to the identification of a clinical candidate, CHS-114, which is in development for cancer immunotherapy [4] - Vaccinex's technology is positioned to address high-value targets that have shown low efficacy or high toxicity with small molecule drugs [4]

ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-negative, head and neck cancer (HNSCC). In a presentation at Society for Immu ...